BR112023004691A2 - Um sistema para melhorar o controle hemostático - Google Patents

Um sistema para melhorar o controle hemostático

Info

Publication number
BR112023004691A2
BR112023004691A2 BR112023004691A BR112023004691A BR112023004691A2 BR 112023004691 A2 BR112023004691 A2 BR 112023004691A2 BR 112023004691 A BR112023004691 A BR 112023004691A BR 112023004691 A BR112023004691 A BR 112023004691A BR 112023004691 A2 BR112023004691 A2 BR 112023004691A2
Authority
BR
Brazil
Prior art keywords
tissue factor
protein
thrombin
wound
present
Prior art date
Application number
BR112023004691A
Other languages
English (en)
Inventor
Winther Lars
Aadal Nielsen Peter
Bækgaard Osther Kurt
Videbæk Charlotte
Original Assignee
Tissue Link Aps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tissue Link Aps filed Critical Tissue Link Aps
Publication of BR112023004691A2 publication Critical patent/BR112023004691A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
    • A61L15/24—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
    • A61L15/28—Polysaccharides or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42—Use of materials characterised by their function or physical properties
    • A61L15/44—Medicaments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Materials Engineering (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Materials For Medical Uses (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Electrotherapy Devices (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Selective Calling Equipment (AREA)

Abstract

A presente invenção se refere a um sistema seguro e eficiente para melhorar o controle hemostático por imobilização da proteína Fator Tecidual a um material curativo adequado para ser usado como um curativo para ferimento ou para ser usado em um curativo para ferimento, colocando o Fator Tecidual em contato direto com o ferimento. A presente invenção tem o intuito de usar o Fator Tecidual imobilizado para gerar uma "descarga de trombina", um processo pelo qual a trombina, o constituinte mais importante da cascata de coagulação, é liberada muito rapidamente. Não há liberação sistêmica do Fator Tecidual proteico no leito vascular. O Fator Tecidual de proteína ligado pode ser usado sozinho ou em combinação com outras proteínas humanas ou componentes para otimizar a homeostase.
BR112023004691A 2020-09-16 2021-09-16 Um sistema para melhorar o controle hemostático BR112023004691A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20196512 2020-09-16
PCT/EP2021/075533 WO2022058452A1 (en) 2020-09-16 2021-09-16 A system to improve haemostatic control

Publications (1)

Publication Number Publication Date
BR112023004691A2 true BR112023004691A2 (pt) 2023-05-09

Family

ID=72560354

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023004691A BR112023004691A2 (pt) 2020-09-16 2021-09-16 Um sistema para melhorar o controle hemostático

Country Status (9)

Country Link
US (1) US20230338480A1 (pt)
EP (1) EP4213865A1 (pt)
JP (1) JP2023541650A (pt)
KR (1) KR20230113529A (pt)
CN (1) CN116322745A (pt)
AU (1) AU2021346280A1 (pt)
BR (1) BR112023004691A2 (pt)
CA (1) CA3190912A1 (pt)
WO (1) WO2022058452A1 (pt)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6762336B1 (en) 1998-01-19 2004-07-13 The American National Red Cross Hemostatic sandwich bandage
US6733774B2 (en) 2001-01-25 2004-05-11 Nycomed Pharma As Carrier with solid fibrinogen and solid thrombin
KR101213460B1 (ko) 2003-01-20 2012-12-20 잇판자이단호진 가가쿠오요비겟세이료호겐쿠쇼 지혈용 재료
EP1812032A4 (en) 2004-10-27 2009-09-02 Univ Illinois TISSUE FACTOR COMPOSITION AND METHOD
WO2012142317A1 (en) 2011-04-15 2012-10-18 Gamma Therapeutics, Inc Fast-clotting wound dressings
US10123908B2 (en) 2011-07-10 2018-11-13 Coloplast A/S Method of preparing a wound care device
EP3274367A1 (en) 2015-03-23 2018-01-31 Dana Genetic A/S Recombinant soluble human tissue factor, method of its production and uses thereof

Also Published As

Publication number Publication date
AU2021346280A1 (en) 2023-05-25
EP4213865A1 (en) 2023-07-26
CN116322745A (zh) 2023-06-23
US20230338480A1 (en) 2023-10-26
CA3190912A1 (en) 2022-03-24
KR20230113529A (ko) 2023-07-31
JP2023541650A (ja) 2023-10-03
WO2022058452A1 (en) 2022-03-24

Similar Documents

Publication Publication Date Title
Iqbal et al. Management of chronic non-healing wounds by hirudotherapy
Etulain et al. An optimised protocol for platelet-rich plasma preparation to improve its angiogenic and regenerative properties
Jeon et al. Plasminogen activator inhibitor type 1 regulates microglial motility and phagocytic activity
Thompson et al. Angiogenic activity of fibrin degradation products is located in fibrin fragment E
Kim et al. Application of platelet-rich plasma accelerates the wound healing process in acute and chronic ulcers through rapid migration and upregulation of cyclin A and CDK4 in HaCaT cells
Lewis et al. Comparison of regenerated and non-regenerated oxidized cellulose hemostatic agents
JP6000974B2 (ja) ウイルス不活化血小板抽出物、その使用及び調製
Giusti et al. Leukocyte depletion does not affect the in vitro healing ability of platelet rich plasma
Morton et al. Wound healing update
Kleinman et al. Thymosin β4 promotes dermal healing
Kwaan et al. Fibrinolytic activity in lesions of hereditary hemorrhagic telangiectasia
Lee et al. Haemophilia and advanced fibrin sealant technologies
Bazrafshan et al. Activation of mitosis and angiogenesis in diabetes-impaired wound healing by processed human amniotic fluid
Honnegowda et al. Effect of limited access dressing on hydroxyproline and enzymatic antioxidant status in nonhealing chronic ulcers
Sambasivan et al. A highly porous silica and chitosan-based hemostatic dressing is superior in controlling hemorrhage in a severe groin injury model in swine
WO2017117996A1 (zh) 一种外科止血生物制品及其使用方法
Jiao et al. Remote ischemic preconditioning protects against cerebral ischemia injury in rats by upregulating miR-204-5p and activating the PINK1/Parkin signaling pathway
Egea-Guerrero et al. Resuscitative goals and new strategies in severe trauma patient resuscitation
BR112023004691A2 (pt) Um sistema para melhorar o controle hemostático
Zitta et al. Profiling of cell stress protein expression in cardiac tissue of cardiosurgical patients undergoing remote ischemic preconditioning: implications for thioredoxin in cardioprotection
JP2022516229A (ja) 多血小板血漿を自己由来トロンビンと組み合わせることにより得ることが可能な創傷処置ゲル
Sabe et al. Extracellular vesicle therapy attenuates antiangiogenic signaling in ischemic myocardium of swine with metabolic syndrome
CA3190932A1 (en) Storage stable films comprising fibrin and/or fibrinogen
Ramey‐Ward et al. Human keratin matrices promote wound healing by modulating skin cell expression of cytokines and growth factors
Zhou et al. Non-cross-linked collagen type I microfibers for improved hemostasis and wound healing